News

When performed by itself, endovascular therapy had greater rates of intracranial hemorrhage compared to a combination of both endovascular therapy and intravenous thrombolysis.

An overview on the Peer Exchange series, "Managing OFF Episodes in Parkinson disease."

The director of the Parkinson's Disease and Movement Disorders Center of Boca Raton spoke to the challenges which remain in addressing OFF episodes in treating Parkinson disease.

The drug was previously approved for the treatment of acute repetitive seizures and granted 7 years of orphan drug exclusivity in January 2020.

This included the first 34 participants from the VISIONARY-MS study, which is currently ongoing with the orally delivered suspension of clean-surfaced, faceted gold nanocrystals.

Addressing risk factors early on may help curb the negative effects of cerebral small vessel disease on aging and reduce risk of neurovascular events.

NeurologyLive's editor in chief Stephen D. Silberstein, MD, discussed the ways to optimizing patient care.

The NeuroEyeCoach visual rehabilitation therapy applied after stroke or other traumatic brain injury (TBI) improved vision in over 80 percent of patients

Gaboxadol is the first treatment in 50 years associated with positive change in outcomes in Angelman syndrome.

Neurology News Network for the week ending February 29, 2020.

The president and founder of Cure Rare Disease discussed the company’s custom therapeutics for patients with rare diseases, including the use of CRISPR gene-editing technology to develop treatments for Duchenne muscular dystrophy.

Recovery status may be a useful tool to predict long-term outcomes in patients with relapsing forms of multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 28, 2020.

Leaders of the CMSC Working Group on MRI protocols and clinical guidelines express the need for a unified approach to diagnosing and monitoring multiple sclerosis.

The investigational MS therapy is currently under review with the FDA, with a PDUFA date set for June 2020.

The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health spoke to the need for data on the proper sequencing strategies for patients with MS who are switching disease-modifying therapies.

Rimegepant, the only orally disintegrating anti-CGRP tablet, marketed as Nurtec ODT, will be available in a 75-mg dose.

Compared with patients who initially received interferon treatment, those given ocrelizumab had superior disability progression after a 6-year follow-up.

Patients with a disease duration of <16 years demonstrated a significantly greater reduction in risk for confirmed disability progression (CDP) at 3 and 6 months.

The new PDUFA action date has been set as June 25, 2020, a 3-month extension. The FDA informed Zogenix that additional data submission has constituted a major amendment to the NDA.

Understanding the pathophysiology of myasthenia gravis is still being determined to this day, but the neonatal Fc receptor is emerging as a potential treatment.

Imad Najm, MD, director of the Cleveland Clinic Epilepsy Center, detailed the ongoing efforts to transform the way health care providers diagnose and treat patients with 1 ultimate goal in mind: improving access to high-quality care.

The orally administered tyrosine kinase inhibitor was shown to delay disability progression in patients with primary progressive multiple sclerosis.

The multi-part series features a panel of 5 distiguished experts, discussing topics related to the updates to MRI and guidelines for multiple sclerosis treatment.

Phase 2 STOP-AUST data suggest that the antifibrinolytic agent may be able to reduce ICH in spot sign positive patients with stroke when administered within 2 to 3 hours of onset, warranting further study.

The Healey ALS Platform Trial learns from successful cancer drug studies to identify and accelerate new treatments for the devastating disease.

The executive director of clinical research at Sunovion spoke about the key takeaways from a phase 3 trial of self-administered apomorphine sublingual film in Parkinson disease.

Based on current evidence, the Task Force was unable to recommend cognitive screening for older adults despite a recent push by the AAN to screen all adults 65 and older for thinking and memory problems.